Medical Pharmacology: Chapter 27 — Gastrointestinal Pharmacology -- Module 4 — Inflammatory Bowel Disease Pharmacology, Part 2: Biologics and Small Molecules (Tier 4: Extended Clinical Cases)

Chapter 27 — Gastrointestinal Pharmacology — Module 4 — Inflammatory Bowel Disease Pharmacology, Part 2: Biologics and Small Molecules (Tier 4: Extended Clinical Cases)

1. [CASE 1 — QUESTION 1] R.K. is a 36-year-old man with newly diagnosed moderate to severe ileocolonic Crohn's disease that has not responded adequately to corticosteroids and a thiopurine. The team plans to start an anti-TNF biologic. Pre-biologic screening returns a positive interferon-gamma release assay (IGRA) with a normal chest X-ray and no pulmonary symptoms, consistent with latent tuberculosis. What is the most appropriate action regarding tuberculosis before starting the anti-TNF agent?

A) Start the anti-TNF agent now and begin tuberculosis therapy only if active disease emerges
B) Treat the latent tuberculosis with isoniazid for at least 4 weeks before initiating the anti-TNF agent
C) Permanently avoid anti-TNF therapy because latent tuberculosis is an absolute lifelong contraindication
D) Administer the BCG vaccine and start the anti-TNF agent on the same day
E) Proceed immediately because a normal chest X-ray excludes any tuberculosis risk

ANSWER: B

Rationale:

Because TNF-alpha maintains granuloma integrity, anti-TNF neutralization can release latent Mycobacterium tuberculosis, so latent tuberculosis must be treated with isoniazid for at least 4 weeks before initiating the biologic.

Option A: Option A incorrectly starts the biologic before treating latent infection, exposing the patient to reactivation precisely when granuloma integrity is compromised.
Option C: Option C overstates latent tuberculosis as an absolute lifelong contraindication, when it can be treated and the biologic then started.
Option D: Option D incorrectly recommends BCG, a live vaccine that is contraindicated in this setting and does not treat latent infection.
Option E: Option E incorrectly claims a normal chest X-ray excludes risk, when the positive IGRA itself indicates latent infection requiring treatment.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. R.K.'s remaining pre-biologic serologies return, and he is found to be hepatitis B surface antigen (HBsAg)-positive. His latent tuberculosis is being treated. What is the most appropriate hepatitis B management as the anti-TNF agent is started?

A) No hepatitis B intervention is needed because anti-TNF agents do not affect viral replication
B) Administer the hepatitis B vaccine series and proceed without antiviral therapy
C) Withhold all biologic therapy permanently because HBsAg positivity is an absolute contraindication
D) Begin antiviral prophylaxis and continue it throughout biologic therapy and for 6 to 12 months after the biologic is stopped
E) Check liver enzymes monthly and start antiviral therapy only if a hepatitis flare develops

ANSWER: D

Rationale:

HBsAg-positive patients are at risk of hepatitis B reactivation during immunosuppression, so antiviral prophylaxis must be started and continued throughout biologic therapy and for 6 to 12 months after the biologic is stopped.

Option A: Option A incorrectly claims no intervention is needed, ignoring the reactivation risk of immunosuppression.
Option B: Option B incorrectly relies on vaccination, which does not protect a patient who is already HBsAg-positive and omits the needed prophylaxis.
Option C: Option C overstates HBsAg positivity as an absolute contraindication, when reactivation risk is managed with antiviral prophylaxis.
Option E: Option E incorrectly waits for a flare, exposing the patient to preventable reactivation during immunosuppression.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. R.K. is started on infliximab. The team elects to continue his thiopurine alongside the infliximab rather than using infliximab alone. What is the principal pharmacological rationale for this combination?

A) The thiopurine reduces formation of anti-drug antibodies against infliximab, raising trough drug concentrations and improving long-term outcomes
B) The thiopurine directly neutralizes additional TNF-alpha, doubling the anti-inflammatory effect
C) The thiopurine accelerates infliximab clearance, allowing a longer dosing interval
D) The thiopurine provides gut-selective targeting that infliximab lacks
E) The thiopurine prevents reactivation of latent tuberculosis during biologic therapy

ANSWER: A

Rationale:

Adding a thiopurine reduces the formation of anti-drug antibodies against infliximab, which raises trough drug concentrations and improves long-term clinical outcomes, an effect demonstrated for infliximab in combination-therapy trials.

Option B: Option B incorrectly claims the thiopurine neutralizes TNF-alpha, which it does not.
Option C: Option C incorrectly states that the thiopurine accelerates clearance, when reducing immunogenicity tends to maintain rather than accelerate drug clearance.
Option D: Option D incorrectly attributes gut-selective targeting to the thiopurine, a property of vedolizumab rather than an immunomodulator.
Option E: Option E incorrectly claims the thiopurine prevents tuberculosis reactivation, when combination immunosuppression actually increases opportunistic infection risk.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. R.K.'s gastroenterologist explains that infliximab is more likely than some other anti-TNF agents to provoke anti-drug antibodies. Which structural feature of infliximab accounts for its relatively higher immunogenicity?

A) It is a PEGylated Fab' fragment lacking the fragment crystallizable (Fc) region
B) It is a fully human IgG1 monoclonal antibody
C) It is a chimeric IgG1 monoclonal antibody containing a murine component, against which anti-drug antibodies commonly form
D) It is an oral small molecule metabolized by hepatic cytochrome enzymes
E) It is a humanized antibody directed against the alpha-4-beta-7 integrin

ANSWER: C

Rationale:

Infliximab is a chimeric IgG1 monoclonal antibody containing a murine component, and anti-drug antibodies directed against that murine portion are the primary mechanism of its relatively higher immunogenicity and secondary loss of response.

Option A: Option A incorrectly describes certolizumab pegol, the Fab' fragment lacking the Fc region.
Option B: Option B incorrectly describes adalimumab, a fully human antibody with lower immunogenicity.
Option D: Option D incorrectly describes a JAK inhibitor; infliximab is an antibody, not a small molecule.
Option E: Option E incorrectly describes vedolizumab, an anti-integrin antibody rather than an anti-TNF agent.

5. [CASE 2 — QUESTION 1] M.T. is a 40-year-old woman with Crohn's disease who achieved remission on infliximab maintenance therapy. After about 14 months, her symptoms return with rising inflammatory markers. Therapeutic drug monitoring (TDM) shows a low trough infliximab concentration with high titers of anti-drug antibodies (ADA). Which interpretation and management are most appropriate?

A) Pharmacokinetic failure; increase the dose or shorten the dosing interval of infliximab
B) Pharmacodynamic failure; continue infliximab unchanged and add only a corticosteroid
C) Primary non-response; discontinue all advanced therapy
D) Adequate therapy; make no change despite symptoms
E) Immunogenic failure; switch to a different anti-TNF agent or to a biologic of a different class

ANSWER: E

Rationale:

A low trough concentration with high anti-drug antibody titers defines immunogenic failure, in which the patient clears the drug through an antibody response, so the appropriate step is to switch to a different anti-TNF agent or to a biologic of a different class rather than escalating.

Option A: Option A misidentifies the pattern as pharmacokinetic failure, which requires low or absent antibodies rather than the high titers present here.
Option B: Option B misidentifies the pattern as pharmacodynamic failure and inappropriately continues a drug that is being neutralized.
Option C: Option C misidentifies secondary loss of response as primary non-response and inappropriately abandons therapy.
Option D: Option D incorrectly calls the therapy adequate despite a subtherapeutic trough and active disease.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. Consider an alternative result: instead of high anti-drug antibodies, M.T.'s testing had shown a low trough infliximab concentration with low (essentially absent) anti-drug antibodies (ADA). How would this pattern be classified and managed?

A) Immunogenic failure; switch to a biologic of a different class immediately
B) Pharmacokinetic failure (drug clearance); increase the dose or shorten the dosing interval to restore a therapeutic trough
C) Pharmacodynamic failure; switch class because the trough is adequate
D) Primary non-response; stop the biologic permanently
E) Laboratory artifact; repeat testing in 6 months and make no change

ANSWER: B

Rationale:

A low trough with low or absent anti-drug antibodies indicates pharmacokinetic failure, also called drug clearance, so the appropriate response is to increase the dose or shorten the dosing interval to restore a therapeutic trough.

Option A: Option A misidentifies the pattern as immunogenic failure, which requires high anti-drug antibodies that are absent here.
Option C: Option C misidentifies the trough as adequate, when the low trough is the abnormality to correct.
Option D: Option D misidentifies secondary loss of response as primary non-response and inappropriately abandons therapy.
Option E: Option E incorrectly dismisses an informative result that clearly indicates pharmacokinetic failure.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. Consider a third possible result: M.T.'s testing instead shows an adequate trough infliximab concentration with no significant anti-drug antibodies (ADA), yet she has clearly lost clinical response. Which interpretation and management are most appropriate?

A) Pharmacodynamic failure (a shift away from a TNF-driven mechanism); switch to a biologic of a different class rather than escalating
B) Pharmacokinetic failure; shorten the dosing interval to raise the trough
C) Immunogenic failure; switch to a different anti-TNF agent to evade antibodies
D) Subtherapeutic dosing; double the infliximab dose
E) Primary non-response; discontinue all advanced therapy

ANSWER: A

Rationale:

An adequate trough with loss of response and no significant anti-drug antibodies defines pharmacodynamic failure, indicating that the inflammation is no longer driven by the targeted pathway, so the correct step is to switch to a biologic of a different class.

Option B: Option B misidentifies the pattern as pharmacokinetic failure, which requires a low trough rather than the adequate trough present here.
Option C: Option C misidentifies the pattern as immunogenic failure, which requires high anti-drug antibodies that are absent.
Option D: Option D incorrectly escalates a drug that already has an adequate level, which will not overcome a mechanism shift.
Option E: Option E misidentifies secondary loss of response as primary non-response and inappropriately abandons therapy.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. Reflecting on M.T.'s loss of response, the team considers how proactive therapeutic drug monitoring (TDM) might have helped earlier. Which statement best describes the rationale for proactive TDM and an appropriate timing point during the first year of therapy?

A) Proactive TDM is performed only after a clinical flare, primarily to reduce drug costs
B) Proactive TDM replaces clinical assessment, so symptoms no longer need monitoring
C) Proactive TDM offers no advantage over reactive testing in preventing immunogenicity
D) Proactive TDM measures trough concentrations on a schedule regardless of symptoms so that subtherapeutic levels are detected early enough to prevent anti-drug antibody development, with measurement recommended at the end of induction around weeks 14 to 16 and after dose changes
E) Proactive TDM is performed once at the end of the first year, after immunogenicity has already developed

ANSWER: D

Rationale:

Proactive TDM measures trough concentrations on a schedule regardless of symptoms so that subtherapeutic levels can be corrected early enough to prevent anti-drug antibody development, with measurement recommended at the end of induction around weeks 14 to 16 and after dose changes.

Option A: Option A incorrectly frames proactive TDM as a flare-triggered cost measure, which describes reactive testing.
Option B: Option B incorrectly claims proactive TDM replaces clinical assessment, when drug levels are interpreted alongside symptoms and biomarkers.
Option C: Option C incorrectly equates proactive and reactive TDM, ignoring the early-detection advantage of scheduled measurement.
Option E: Option E incorrectly delays measurement until immunogenicity has already developed, which defeats the preventive purpose.

9. [CASE 3 — QUESTION 1] D.H. is a 62-year-old man with ulcerative colitis, hypertension, and a prior myocardial infarction. He has had an inadequate response to a TNF inhibitor and now asks specifically about an oral agent. The team considers a Janus kinase (JAK) inhibitor. What is the most appropriate position given the JAK inhibitor black box warning?

A) Start a JAK inhibitor immediately as first-line therapy because oral dosing is most convenient
B) A JAK inhibitor is absolutely contraindicated for life in anyone with prior myocardial infarction
C) A JAK inhibitor is a reasonable candidate given prior TNF inhibitor failure, but because he is aged 50 or older with cardiovascular risk factors and a prior myocardial infarction he is in the highest-risk group of the black box warning, so the decision requires careful risk-benefit assessment and explicit counseling
D) Combine the JAK inhibitor with the prior anti-TNF agent to offset cardiovascular risk
E) A JAK inhibitor is uniformly safer than biologics and needs no cardiovascular assessment

ANSWER: C

Rationale:

Prior TNF inhibitor failure makes a JAK inhibitor a legitimate candidate, but because this patient is aged 50 or older with cardiovascular risk factors and a prior myocardial infarction he falls into the highest-risk group identified by the black box warning, so the decision requires careful risk-benefit assessment and explicit counseling about cardiovascular, thromboembolic, and malignancy risk.

Option A: Option A incorrectly recommends immediate first-line use, contradicting the directive to reserve JAK inhibitors for after TNF inhibitor failure and ignoring his elevated risk.
Option B: Option B overstates the warning as an absolute lifelong contraindication, which it is not.
Option D: Option D incorrectly recommends combining a JAK inhibitor with an anti-TNF agent, which compounds immunosuppression without offsetting cardiovascular risk.
Option E: Option E incorrectly claims uniform safety and waives the cardiovascular assessment the warning requires.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. After a careful discussion, D.H. and his team decide to proceed with a JAK inhibitor. Considering the characteristic adverse-effect profile of JAK inhibitors and the rules for vaccination during immunosuppression, what vaccination approach is correct?

A) Because JAK inhibitors raise the risk of herpes zoster reactivation, give the recombinant (non-live) zoster vaccine before or as early as possible after starting therapy, while live vaccines remain contraindicated during therapy
B) No zoster vaccination is needed because JAK inhibitors do not increase zoster risk
C) Administer the live attenuated zoster vaccine during JAK inhibitor therapy to maximize immunity
D) Zoster vaccination is unnecessary because the only infectious concern with JAK inhibitors is tuberculosis
E) All vaccines, live and non-live, are equally safe and encouraged during JAK inhibitor therapy

ANSWER: A

Rationale:

JAK inhibitors increase the risk of herpes zoster reactivation more than biologics or conventional immunomodulators, so the recombinant (non-live) zoster vaccine should be given before or as early as possible after starting therapy, while live vaccines remain contraindicated during immunosuppression.

Option B: Option B incorrectly denies the elevated zoster risk that characterizes this class.
Option C: Option C incorrectly recommends a live vaccine during immunosuppression, which is contraindicated.
Option D: Option D incorrectly substitutes tuberculosis, an anti-TNF concern, for the characteristic JAK inhibitor zoster signal.
Option E: Option E incorrectly treats live and non-live vaccines as equally safe during immunosuppression, ignoring the live-vaccine contraindication.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. A trainee suggests that if D.H. is given the selective Janus kinase 1 (JAK1) inhibitor upadacitinib, the black box safety concerns will not apply because of its selectivity. Which response correctly integrates the rationale for JAK1 selectivity with the basis of the warning?

A) The trainee is correct; JAK1 selectivity removes both the cytopenia risk and the cardiovascular and thromboembolic risk
B) JAK1 selectivity eliminates the cardiovascular risk but worsens cytopenias relative to pan-JAK agents
C) JAK1 selectivity converts the drug into a biologic, exempting it from small-molecule warnings
D) JAK1 selectivity has no pharmacologic rationale and changes no part of the adverse-effect profile
E) JAK1 selectivity is intended to reduce Janus kinase 2 (JAK2)-mediated effects such as anemia and neutropenia, but the class-wide black box warning for major adverse cardiovascular events, venous thromboembolism, and malignancy still applies to upadacitinib

ANSWER: E

Rationale:

JAK1 selectivity is intended to reduce JAK2-mediated effects such as anemia and neutropenia, but it does not exempt the drug from the class-wide black box warning, so the warning for major adverse cardiovascular events, venous thromboembolism, and malignancy still applies to upadacitinib.

Option A: Option A incorrectly claims selectivity removes the cardiovascular and thromboembolic risk, which remains class-wide.
Option B: Option B incorrectly states that selectivity worsens cytopenias, when the design intent is to reduce them.
Option C: Option C incorrectly claims selectivity turns the small molecule into a biologic, which is false.
Option D: Option D incorrectly denies any pharmacologic rationale for JAK1 selectivity, contradicting its purpose of sparing JAK2-mediated effects.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. The black box warning for JAK inhibitors arose from a post-marketing safety study that compared a JAK inhibitor with TNF inhibitors in older patients with cardiovascular risk factors. Applying the conclusion of that study to D.H., which positioning statement is best supported?

A) The study showed JAK inhibitors reduce cardiovascular events, so they should be first-line in high-risk patients
B) Because the study found higher rates of major adverse cardiovascular events, malignancy, and venous thromboembolism with the JAK inhibitor in this higher-risk population, JAK inhibitors should generally be reserved for patients with an inadequate response to or intolerance of one or more TNF inhibitors, with particular caution in patients aged 50 or older with cardiovascular risk factors
C) The study findings apply only to rheumatoid arthritis and have no bearing on inflammatory bowel disease prescribing
D) The study supports combining a JAK inhibitor with an anti-TNF agent to balance the risks
E) The study established that JAK inhibitors carry no malignancy risk

ANSWER: B

Rationale:

The study found higher rates of major adverse cardiovascular events, malignancy, and venous thromboembolism with the JAK inhibitor compared with TNF inhibitors in an older, higher-risk population, so the applied conclusion is that JAK inhibitors should generally be reserved for patients with an inadequate response to or intolerance of one or more TNF inhibitors, with particular caution in patients aged 50 or older who have cardiovascular risk factors.

Option A: Option A inverts the finding, since the study showed increased rather than decreased cardiovascular events.
Option C: Option C incorrectly dismisses the finding as irrelevant to inflammatory bowel disease, when it drove a class-wide warning across indications.
Option D: Option D incorrectly recommends combining a JAK inhibitor with an anti-TNF agent, which compounds risk rather than balancing it.
Option E: Option E incorrectly claims no malignancy risk, contradicting the study's malignancy signal.

13. [CASE 4 — QUESTION 1] S.A. is a 74-year-old woman with moderate to severe ulcerative colitis and a history of recurrent pneumonia and one prior episode of sepsis. She now needs advanced therapy. Which biologic is best supported as the preferred choice given her infection risk?

A) Infliximab, because intravenous dosing ensures the most reliable response in elderly patients
B) A Janus kinase (JAK) inhibitor, because the oral route removes infection risk
C) Combination anti-TNF plus azathioprine, to maximize remission rates
D) Vedolizumab, because its gut-selective alpha-4-beta-7 blockade preserves systemic immune surveillance and carries a favorable systemic infection profile, making it preferred in elderly or high-infection-risk patients
E) Adalimumab, because subcutaneous dosing avoids systemic infection risk

ANSWER: D

Rationale:

Vedolizumab's gut-selective alpha-4-beta-7 blockade compartmentalizes immunosuppression to the intestine and preserves systemic immune surveillance, giving it a favorable systemic infection profile and making it the preferred biologic in elderly or high-infection-risk patients.

Option A: Option A incorrectly implies the intravenous route mitigates the systemic infection risk inherent to anti-TNF therapy.
Option B: Option B incorrectly claims the oral route removes infection risk, when JAK inhibitors carry a black box warning that includes serious infections.
Option C: Option C incorrectly maximizes immunosuppression and therefore infection risk, the opposite of what this patient needs.
Option E: Option E incorrectly attributes reduced systemic infection risk to the subcutaneous route, which does not change the systemic effect of TNF neutralization.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. S.A.'s family asks why she did not need the latent tuberculosis screening that an anti-TNF agent would have required. Which explanation correctly integrates the immunologic role of TNF-alpha with vedolizumab's mechanism?

A) Vedolizumab neutralizes TNF more selectively, so granulomas stay intact while anti-TNF agents do not affect granulomas at all
B) Both drugs suppress systemic immunity equally, but vedolizumab's screening requirement was simply never studied
C) TNF-alpha maintains granuloma integrity, so anti-TNF neutralization can release latent mycobacteria and mandates screening, whereas vedolizumab's alpha-4-beta-7 blockade is compartmentalized to gut-homing lymphocytes and preserves the systemic immunity that contains latent tuberculosis
D) Vedolizumab accelerates clearance of mycobacteria, eliminating any need for screening
E) Screening requirements are arbitrary regulatory precedent unrelated to drug mechanism

ANSWER: C

Rationale:

TNF-alpha is essential for maintaining the granulomas that contain latent Mycobacterium tuberculosis, so neutralizing TNF can release viable organisms and mandates screening, whereas vedolizumab blocks the alpha-4-beta-7 integrin on gut-homing lymphocytes in a compartmentalized manner that preserves the systemic immunity containing latent tuberculosis.

Option A: Option A incorrectly states that vedolizumab neutralizes TNF, which it does not, and wrongly claims anti-TNF agents leave granulomas unaffected.
Option B: Option B incorrectly claims both drugs suppress systemic immunity equally, ignoring vedolizumab's gut selectivity.
Option D: Option D fabricates a mycobacterial clearance effect that vedolizumab does not have.
Option E: Option E incorrectly reduces the screening requirement to arbitrary precedent rather than granuloma biology.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. Several months later, before vedolizumab could be initiated, S.A. presents with an acute severe flare requiring rapid disease control. The team must choose an agent that will work quickly. Which choice is best supported by the onset characteristics of the agents?

A) Vedolizumab, because its gut-selective action produces the fastest response in acute severe disease
B) An anti-TNF agent, because anti-TNF biologics act more rapidly than vedolizumab, whose slower onset makes it ill-suited to acute severe disease where rapid control is needed
C) Vedolizumab, because onset speed does not matter in severe disease
D) Risankizumab, because selective interleukin-23 (IL-23) p19 blockade guarantees an immediate response
E) Any advanced therapy, because all agents have identical onset times

ANSWER: B

Rationale:

Anti-TNF agents act more rapidly than vedolizumab, whose onset is slower and may require weeks to reach meaningful effect, so an anti-TNF agent is better suited when rapid control of an acute severe flare is needed.

Option A: Option A incorrectly claims vedolizumab is fastest, when its slower onset is precisely what limits its use in this setting.
Option C: Option C incorrectly dismisses onset speed, which is central to managing acute severe disease.
Option D: Option D incorrectly asserts an immediate response from risankizumab, which is not characterized by rapid onset in acute severe disease.
Option E: Option E incorrectly claims identical onset times across agents, ignoring well-described differences.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. After recovery, S.A. develops prominent peripheral inflammatory arthritis that significantly affects her function, in addition to her colitis. Considering both her intestinal and extraintestinal disease, which long-term choice is best supported?

A) Vedolizumab, because its gut-selective action best controls extraintestinal arthritis
B) Aminosalicylate monotherapy, because it adequately treats both joint and bowel disease
C) A Janus kinase (JAK) inhibitor as mandatory first-line therapy for any extraintestinal manifestation
D) Vedolizumab plus an aminosalicylate, because the combination covers extraintestinal disease
E) An anti-TNF agent or ustekinumab, because systemically active agents address prominent extraintestinal manifestations, whereas gut-selective vedolizumab acts mainly within the intestine and is less suited when significant extraintestinal disease is present

ANSWER: E

Rationale:

Systemically active agents such as anti-TNF biologics or ustekinumab are preferred when prominent extraintestinal manifestations are present, because gut-selective vedolizumab acts mainly within the intestine and is less suited to controlling significant extraintestinal disease.

Option A: Option A incorrectly claims vedolizumab best controls extraintestinal arthritis, contradicting its gut-compartmentalized action.
Option B: Option B incorrectly relies on aminosalicylate monotherapy, which is inadequate for moderate to severe disease with significant extraintestinal involvement.
Option C: Option C incorrectly mandates a JAK inhibitor first-line for any extraintestinal manifestation, ignoring the directive to reserve JAK inhibitors after TNF inhibitor failure.
Option D: Option D incorrectly pairs gut-selective vedolizumab with an aminosalicylate, neither of which reliably controls prominent extraintestinal arthritis.

17. [CASE 5 — QUESTION 1] J.P. is a 45-year-old man with moderate to severe Crohn's disease for whom the team is selecting among cytokine-directed biologics. The first agent under discussion is ustekinumab. Which cytokine target correctly describes ustekinumab's mechanism?

A) The p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking both cytokines
B) The interleukin-23 (IL-23) p19 subunit only, sparing interleukin-12 (IL-12)
C) Soluble and transmembrane TNF-alpha
D) The alpha-4-beta-7 integrin on gut-homing lymphocytes
E) The intracellular Janus kinase 1 (JAK1) enzyme

ANSWER: A

Rationale:

Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, thereby blocking both cytokines; IL-12 drives Th1 differentiation while IL-23 amplifies Th17 cells, and blocking the common p40 subunit inhibits both pathways.

Option B: Option B incorrectly describes risankizumab, which selectively blocks only the IL-23 p19 subunit and spares IL-12.
Option C: Option C incorrectly describes the anti-TNF agents.
Option D: Option D incorrectly describes vedolizumab.
Option E: Option E incorrectly describes a JAK inhibitor, an intracellular small molecule rather than an antibody.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. The team also considers risankizumab and discusses how it differs from ustekinumab. What is the conceptual consequence of risankizumab's selective interleukin-23 (IL-23) p19 blockade compared with ustekinumab's p40 blockade?

A) Sparing interleukin-12 (IL-12) eliminates efficacy in Crohn's disease because IL-12 is the dominant driver
B) Sparing interleukin-12 (IL-12) converts the antibody into an oral small molecule
C) Sparing interleukin-12 (IL-12) increases cardiovascular risk to match that of Janus kinase (JAK) inhibitors
D) By selectively blocking IL-23 p19 and sparing IL-12, risankizumab preserves IL-12-dependent protective immunity, including antiviral and antimycobacterial responses, because the IL-23-driven Th17 pathway rather than the IL-12-driven Th1 pathway is the dominant pathological mechanism in inflammatory bowel disease
E) Sparing interleukin-12 (IL-12) removes the need for any infection screening that ustekinumab requires

ANSWER: D

Rationale:

Because the IL-23-driven Th17 pathway rather than the IL-12-driven Th1 pathway is the dominant pathological mechanism in inflammatory bowel disease, selectively blocking IL-23 p19 is sufficient for efficacy while sparing IL-12 preserves IL-12-dependent protective immunity, including antiviral and antimycobacterial defenses.

Option A: Option A incorrectly designates IL-12 as the dominant driver, when the IL-23/Th17 axis predominates.
Option B: Option B incorrectly suggests target selectivity changes the molecule into an oral small molecule, which it does not.
Option C: Option C incorrectly links IL-12 sparing to JAK inhibitor cardiovascular risk, an unrelated class concern.
Option E: Option E incorrectly claims IL-12 sparing removes screening requirements, conflating cytokine selectivity with infection-screening protocols.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. J.P. and the team decide on ustekinumab. Which dosing pattern correctly describes ustekinumab in inflammatory bowel disease?

A) 5 mg/kg intravenously at weeks 0, 2, and 6, then every 8 weeks
B) 40 mg subcutaneously every 2 weeks after a loading dose
C) A single weight-based intravenous induction dose of approximately 6 mg/kg, followed by 90 mg subcutaneously every 8 or 12 weeks
D) 10 mg orally twice daily for induction, then 5 mg twice daily
E) 300 mg intravenously at weeks 0, 2, and 6, then every 8 weeks

ANSWER: C

Rationale:

Ustekinumab is given as a single weight-based intravenous induction dose of approximately 6 mg/kg, followed by 90 mg subcutaneously every 8 or 12 weeks for maintenance.

Option A: Option A incorrectly describes infliximab's weight-based infusion schedule.
Option B: Option B incorrectly describes the adalimumab subcutaneous maintenance regimen.
Option D: Option D incorrectly describes an oral tofacitinib regimen.
Option E: Option E incorrectly describes vedolizumab's fixed 300 mg intravenous schedule, not ustekinumab.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. As J.P. begins ustekinumab, the team sets a treatment goal using the treat-to-target principle. What is the appropriate treatment goal under this principle?

A) Complete withdrawal of all therapy once symptoms resolve
B) Deeper remission, defined as histological remission in ulcerative colitis and transmural (imaging) remission in Crohn's disease, rather than symptom control alone
C) Maintaining the lowest possible drug trough concentration to limit cost
D) Symptom control alone, because endoscopic and histological endpoints do not affect outcomes
E) Permanent corticosteroid maintenance to suppress all inflammation

ANSWER: B

Rationale:

Treat-to-target sets the goal as deeper remission, histological remission in ulcerative colitis and transmural remission assessed by imaging in Crohn's disease, rather than symptom relief alone, because objective mucosal and transmural healing correlates with better long-term outcomes.

Option A: Option A incorrectly stops all therapy on symptom resolution, which risks relapse.
Option C: Option C incorrectly defines the target by minimizing trough levels for cost rather than by disease remission endpoints.
Option D: Option D incorrectly treats symptom control as sufficient, contradicting the principle.
Option E: Option E incorrectly relies on chronic corticosteroid maintenance, which is specifically avoided in inflammatory bowel disease due to toxicity and is not a treat-to-target strategy.

21. [CASE 6 — QUESTION 1] L.M. is a 30-year-old pregnant woman with Crohn's disease, now in her third trimester, whose disease requires continued anti-TNF therapy through delivery. The team selects the anti-TNF agent with the most favorable placental-transfer profile. Which agent is preferred, and on what structural basis?

A) Infliximab, because the infusion can be timed near delivery to limit transfer
B) Adalimumab, because its fully human structure prevents placental transfer
C) Golimumab, because monthly dosing reduces cumulative transfer
D) Any anti-TNF agent equally, because none crosses the placenta in the third trimester
E) Certolizumab pegol, because it is a Fab' fragment lacking the fragment crystallizable (Fc) region and therefore is not transported across the placenta by the neonatal Fc receptor

ANSWER: E

Rationale:

Certolizumab pegol lacks the Fc region required for neonatal Fc receptor–mediated placental transfer, so minimal drug reaches the fetus, making it the preferred anti-TNF agent when therapy must continue into the third trimester.

Option A: Option A incorrectly suggests infusion timing prevents transfer, when infliximab is a full IgG1 antibody that crosses the placenta in the third trimester.
Option B: Option B incorrectly claims a fully human structure prevents transfer, when adalimumab is a complete IgG1 antibody that does transfer.
Option C: Option C incorrectly attributes reduced transfer to golimumab's dosing interval, when it is also a full IgG1 antibody.
Option D: Option D incorrectly treats the anti-TNF agents as equivalent, when the full IgG1 antibodies cross the placenta but certolizumab essentially does not.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. Consider an alternative scenario in which L.M. had instead remained on infliximab past 22 weeks of gestation rather than switching agents. What counseling about the infant's immunizations would be correct in that situation?

A) The infant requires lifelong avoidance of all vaccines because of in utero anti-TNF exposure
B) No precautions are needed because infliximab does not cross the placenta at any gestational age
C) Because infliximab is a full IgG1 antibody that transfers across the placenta in the third trimester, the infant's live vaccines should be delayed until about 6 months of age when the mother received anti-TNF therapy after 22 weeks
D) The infant should receive extra early live vaccines to compensate for transient immunosuppression
E) Certolizumab and infliximab behave identically in pregnancy, so no agent-specific counseling applies

ANSWER: C

Rationale:

Infliximab is a full IgG1 antibody that transfers across the placenta in the third trimester, so when the mother received anti-TNF therapy after 22 weeks, the infant's live vaccines should be delayed until about 6 months of age to avoid live immunization during the period of residual drug exposure.

Option A: Option A incorrectly imposes lifelong vaccine avoidance, which is not the recommendation.
Option B: Option B incorrectly claims infliximab does not cross the placenta, contradicting its third-trimester transfer.
Option D: Option D incorrectly recommends extra early live vaccines during the period of residual exposure.
Option E: Option E incorrectly equates certolizumab with infliximab, when certolizumab's lack of an Fc region makes its placental transfer minimal and its counseling different.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. L.M. asks whether any non–anti-TNF advanced therapies could be continued during pregnancy if her disease activity required it. Which statement is most accurate regarding pregnancy use of these agents?

A) Vedolizumab and ustekinumab may be continued in pregnancy if the benefit outweighs the risk
B) All biologics are absolutely contraindicated throughout pregnancy without exception
C) Janus kinase (JAK) inhibitors are the preferred agents during pregnancy because of their oral route
D) Aminosalicylates must replace all biologics for the entire pregnancy regardless of disease activity
E) Only intravenous agents are safe in pregnancy because subcutaneous agents reach the fetus

ANSWER: A

Rationale:

Vedolizumab and ustekinumab may be continued during pregnancy when the benefit outweighs the risk, allowing disease control to be maintained with agents that have reassuring pregnancy data.

Option B: Option B incorrectly imposes an absolute contraindication on all biologics, which is not the case.
Option C: Option C incorrectly recommends JAK inhibitors in pregnancy, when these oral small molecules are not preferred and carry reproductive concerns.
Option D: Option D incorrectly forces a switch to aminosalicylates regardless of disease activity, which would undertreat moderate to severe disease.
Option E: Option E incorrectly claims route of administration determines fetal safety, which is not the basis for agent selection in pregnancy.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. To consolidate the teaching point, the team asks why certolizumab pegol, unlike the other anti-TNF agents, does not appreciably cross the placenta. Which explanation is correct?

A) Certolizumab is an oral small molecule cleared before reaching the fetal circulation
B) Certolizumab binds the fetal hepatic receptors, preventing its own transfer
C) Certolizumab is too small a molecule to enter the maternal circulation at all
D) Certolizumab is a Fab' fragment that lacks the fragment crystallizable (Fc) region, and because third-trimester placental IgG transfer depends on the neonatal Fc receptor binding the Fc region, certolizumab is not transported across the placenta
E) Certolizumab is destroyed by placental enzymes that spare full IgG antibodies

ANSWER: D

Rationale:

Third-trimester placental transfer of IgG depends on the neonatal Fc receptor binding the Fc region of the antibody; because certolizumab pegol is a Fab' fragment that lacks the Fc region, it is not transported across the placenta, unlike the full IgG1 anti-TNF antibodies.

Option A: Option A incorrectly describes certolizumab as an oral small molecule, when it is an injectable antibody fragment.
Option B: Option B fabricates a fetal hepatic receptor mechanism that does not explain the lack of transfer.
Option C: Option C incorrectly claims the molecule does not enter the maternal circulation, when certolizumab is administered systemically and acts on maternal TNF.
Option E: Option E fabricates a selective placental enzyme mechanism that does not account for the difference.